Mayo Clinic researchers have developed a new way to predict whether existing drugs could be repurposed to treat heart failure ...

When Sherry Mansour, MD, assistant professor of medicine (nephrology), first began her training at Yale, she was struck by the high rates of heart failure among her patients with kidney disease.

Rochester, Minn.-based Mayo Clinic has developed a framework that uses computer modeling and electronic health records to simulate “virtual clinical trials” for heart failure treatments. Researchers ...

Bayer's mineralocorticoid receptor antagonist (MRA) Kerendia has won FDA approval for a new heart failure indication thought to be pivotal for the product's sales prospects. The US regulator has ...